ArticleClinical cancer research : an official journal of the American Association for Cancer Research2026
Circadian Genotypes in PER3 and Time of Prostate Cancer Radiotherapy Interact to Affect Risk of Late Side Effects.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Funding
Abstract
purposeWe showed previously that patients with breast cancer with certain circadian rhythm genotypes have higher incidences of toxicity when treated with radiotherapy at different times of day. This opens the way to genetically guided chronomodulation as a cost-effective way to reduce side effects while preserving treatment efficacy. We aimed to test whether similar time-of-day effects are observed in prostate cancer. EXPERIMENTAL
designThe analysis used the multinational, prospective observational REQUITE prostate cancer cohort (n = 1,760). All patients received external beam radiotherapy and were followed for 2 years.Regression analyses were performed in patients with complete data, including genotypes and radiotherapy fraction times (n = 877). Least absolute shrinkage and selection operator (LASSO) and logistic regression models incorporated genotypes of single-nucleotide polymorphisms in circadian rhythm genes, time of radiotherapy, and their interaction. Primary endpoints were late rectal bleeding (RB) and urinary incontinence (UI).
resultsMultivariable models show significant effects of genotype, treatment timing, and the interaction between PER3 genotypes and treatment timing for both primary endpoints. The 44% of patients with the rs696305 C/C genotype are predicted to reduce their risk of RB from 11% when treated at 9:00 am to 5% when treated at 5:00 pm. Similarly, the analysis predicts a significant reduction in the risk of UI from 15% to 5% by avoiding treatment in the middle of the day for patients heterozygous for rs172933 (36% of patients).
conclusionsThese results agree with the earlier findings in patients with breast cancer who have undergone radiotherapy. The interaction between genotype and time of treatment suggests that groups of patients could reduce side effects and improve their quality of life through chronomodulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.